Literature DB >> 18515882

Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.

Maurizio Zangari, Jose Guerrero, Federica Cavallo, H Keshava Prasad, Dixie Esseltine, Louis Fink.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18515882     DOI： 10.3324/haematol.12522

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

1.  Proteasome proteolysis supports stimulated platelet function and thrombosis.

Authors:  Nilaksh Gupta; Wei Li; Belinda Willard; Roy L Silverstein; Thomas M McIntyre
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-31       Impact factor: 8.311

2.  Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.

Authors:  Rajshekhar Chakraborty; Irbaz Bin Riaz; Saad Ullah Malik; Naimisha Marneni; Alex Mejia Garcia; Faiz Anwer; Alok A Khorana; S Vincent Rajkumar; Shaji Kumar; M Hassan Murad; Zhen Wang; Safi U Khan; Navneet S Majhail
Journal:  Cancer       Date:  2020-01-08       Impact factor: 6.860

3.  Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children.

Authors:  José A Guerrero; José Rivera; Teresa Quiroga; Angel Martinez-Perez; Ana Isabel Antón; Constantino Martínez; Olga Panes; Vicente Vicente; Diego Mezzano; José-Manuel Soria; Javier Corral
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

4.  The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2).

Authors:  Lalitha Nayak; Hong Shi; G Brandon Atkins; Zhiyong Lin; Alvin H Schmaier; Mukesh K Jain
Journal:  Blood       Date:  2014-04-25       Impact factor: 22.113

5.  Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.

Authors:  Kristen M Sanfilippo; Suhong Luo; Tzu-Fei Wang; Mark Fiala; Martin Schoen; Tanya M Wildes; Joseph Mikhael; Nicole M Kuderer; David C Calverley; Jesse Keller; Theodore Thomas; Kenneth R Carson; Brian F Gage
Journal:  Am J Hematol       Date:  2019-08-19       Impact factor: 10.047

6.  A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

Authors:  Jesús F San-Miguel; Maria-Asunción Echeveste Gutierrez; Ivan Špicka; María-Victoria Mateos; Kevin Song; Michael D Craig; Joan Bladé; Roman Hájek; Christine Chen; Alessandra Di Bacco; Jose Estevam; Neeraj Gupta; Catriona Byrne; Vickie Lu; Helgi van de Velde; Sagar Lonial
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.